Tuesday, February 7, 8:44 AM
Merck (MRK) announces that top-line results of a study on Vorapaxar show that the drug significantly reduced the risk of cardiovascular events. The company plans to release full results in March.
This Market Current was sent to 3,623 people who get email alerts on MRK.
